Globus Medical (GMED) Stock Overview
Develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GMED from our risk checks.
GMED Community Fair Values
Create NarrativeSee what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.
Globus Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$86.16 |
| 52 Week High | US$101.40 |
| 52 Week Low | US$51.79 |
| Beta | 1.07 |
| 1 Month Change | -9.74% |
| 3 Month Change | -1.32% |
| 1 Year Change | 17.40% |
| 3 Year Change | 49.66% |
| 5 Year Change | 35.07% |
| Change since IPO | 538.22% |
Recent News & Updates
Recent updates
Globus Medical: Great Value, Momentum, And Earnings Growth
Mar 19Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Sep 12
What You Can Learn From Globus Medical, Inc.'s (NYSE:GMED) P/E
Jul 21Globus Medical, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 11At US$71.91, Is It Time To Put Globus Medical, Inc. (NYSE:GMED) On Your Watch List?
May 05Globus Medical: Digesting Another Acquisition
Apr 23An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 38% Undervalued
Apr 20Globus Medical: Some Caution After Its Deal For Nevro
Feb 16Globus Medical Stock: Re-Rated After A Solid Year
Nov 18Globus Medical: A Post Acquisition Analysis
Aug 26
Calculated Initiatives And Innovative Technologies Propel Growth In Medical Equipment Sector
Strategic integration and new product launches aim to increase Globus Medical's market share and future revenue through enhanced offerings.Shareholder Returns
| GMED | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.1% | -1.3% | -0.6% |
| 1Y | 17.4% | -13.5% | 16.0% |
Return vs Industry: GMED exceeded the US Medical Equipment industry which returned -15% over the past year.
Return vs Market: GMED exceeded the US Market which returned 14% over the past year.
Price Volatility
| GMED volatility | |
|---|---|
| GMED Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: GMED has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GMED's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 6,000 | Keith Pfeil | www.globusmedical.com |
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems.
Globus Medical, Inc. Fundamentals Summary
| GMED fundamental statistics | |
|---|---|
| Market cap | US$11.29b |
| Earnings (TTM) | US$537.87m |
| Revenue (TTM) | US$2.94b |
Is GMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMED income statement (TTM) | |
|---|---|
| Revenue | US$2.94b |
| Cost of Revenue | US$938.35m |
| Gross Profit | US$2.00b |
| Other Expenses | US$1.46b |
| Earnings | US$537.87m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.98 |
| Gross Margin | 68.07% |
| Net Profit Margin | 18.30% |
| Debt/Equity Ratio | 0% |
How did GMED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/31 04:34 |
| End of Day Share Price | 2026/03/31 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Globus Medical, Inc. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |